Search

Displaying results 6911 - 6920 of 10000 in total
  1. Drug

    Ivarmacitinib

    go.drugbank.com/drugs/DB16756
    Investigational

    While ivarmactinib has yet to receive marketing authorization, as of February 2022 clinical trials are ongoing or completed evaluating its use in atopic dermatitis,[L40604,L40619,L40629] ankylosing spondylitis

  2. Drug

    HEC-921

    go.drugbank.com/drugs/DB33971
    Experimental

    HEC-921 is under investigation in clinical trial NCT07824934 (HEC-921 Injection as Monotherapy and in Combination With Antineoplastic Therapies in Patients With Advanced Malignant Solid Tumors).

  3. Drug

    Ubamatamab

    go.drugbank.com/drugs/DB18875
    Investigational

    Ubamatamab is under investigation in clinical trial NCT03564340 (Study of REGN4018 Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent

  4. Drug

    Tifcemalimab

    go.drugbank.com/drugs/DB18914
    Investigational

    Tifcemalimab is under investigation in clinical trial NCT06095583 (Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell

  5. Drug

    Cimlanod

    go.drugbank.com/drugs/DB14983
    Investigational

    Cimlanod is under investigation in clinical trial NCT02819271 (A First-in-Human Study of the Safety of Single Continuous Intravenous (IV) Infusions of CXL-1427 for up to 48 Hours in Healthy Volunteers)

  6. Drug

    Alcestobart

    go.drugbank.com/drugs/DB28487
    Investigational

    Alcestobart is under investigation in clinical trial NCT05909904 (A Study of Tislelizumab in Combination With Investigational Agents in Participants With Head and Neck Squamous Cell Carcinoma).

  7. Drug

    Budigalimab

    go.drugbank.com/drugs/DB16668
    Investigational

    Budigalimab is under investigation in clinical trial NCT04807972 (Study to Evaluate Adverse Events and Change in Disease Activity When Intravenous (IV) Infusion of ABBV-927 Is Administered in Combination … With IV Modified FOLFIRINOX (Mffx) With or Without IV Budigalimab Compared to Mffx in Adult Participants With Untreated Pancreatic Cancer Metastasis).

  8. Drug

    Refanezumab

    go.drugbank.com/drugs/DB14908
    Investigational

    Refanezumab is under investigation in clinical trial NCT00833989 (Safety Escalating Repeat IV, in Stroke Patients).

  9. Drug

    Nerinetide

    go.drugbank.com/drugs/DB12595
    Investigational

    Na 1 is under investigation in clinical trial NCT00728182 (Evaluating Neuroprotection in Aneurysm Coiling Therapy).

  10. Drug

    Bifikafusp alfa

    go.drugbank.com/drugs/DB19185
    Investigational

    Bifikafusp alfa is under investigation in clinical trial NCT05329792 (L19IL2/L19TNF in Skin Cancer Patients).

    Synonyms: Immunoglobulin, anti-(human fibronectin ed-b domain) (synthetic human clone l19 scfv fragment) fusion protein with human interleukin 2